Search Results

dose of 2500 units/m2/dose IV on Day 8. Cycles repeated every 28 days until disease progression, transplant, or excessive toxicity development. Peg-filgrastim or filgrastimgiven for neutropenia. Antimicrobial prophylaxis was with acyclovir

Infectious diseases are important causes of morbidity and mortality in patients with cancer. In certain instances, the malignancy itself can predispose patients to severe or recurrent infections. Neutropenia has been recognized for many decades as a major

patients with breast cancer showed that the biosimilar filgrastim was equally effective as the reference product in the prevention of neutropenia in patients receiving myelosuppressive chemotherapy. 3 Filgrastim-sndz was subsequently approved for the

: Panobinostat is associated with a substantially higher odds of anemia, thrombocytopenia, fatigue and diarrhea. However, it has a 75% lower risk of neutropenia and 10% lower risk of grade 3 and 4 complications. Figure 1 Odds ratio of grade 3 and grade 4

-free melphalan and thirty-six received generic melphalan; both groups had similar demographics, performance status and ISS stage ( Table 1 ). There was no statistically significant difference in time to count recovery, toxicities (mucositis, febrile neutropenia

toxicity: leukopenia and neutropenia grade 3–4 in 5 patients (62.5%) and mucosal toxicity: diarrhea grade 2 in 4 (50%) patients, oral mucositis grade 1-2 in 3 (37.5%) and 2 (25%) patients respectively. Conversion rate to negative peritoneal cytology was 80

information, visit NCCN.org/orp . NCCN Releases New Patient Guidelines on Anemia and Neutropenia NCCN has published new NCCN Guidelines for Patients: Anemia and Neutropenia, Low Red and White Blood Cell Counts funded by the NCCN Foundation and

a prospective nationwide study of oncology practice . J Natl Compr Canc Netw 2008 ; 6 : 109 – 118 . 2 Kuderer NM Dale DC Crawford J . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer

years) had improved median PFS and RR but no improvement in median OS. 11 The most common grade 3 or higher AEs in the bevacizumab arm were neutropenia (26%), hypertension (7%), febrile neutropenia (5%), and bleeding events (4%). 9 Compared with

neutropenia (neutrophil count <1,500/mcL) occurring during the first 4 weeks after initiation of treatment. To minimize immortal time bias, follow-up time in this analysis was defined as time in months starting 4 weeks after initiation of treatment. A final